Women's Health - Principal, Venture Capital & Clinician

A principal at a venture capital firm and a former clinician broadly specializes in women’s health. They consider investment, research, gold standard for treatment, treatments, and reimbursement key challenges in this space. They rate unmet needs highest in endometriosis, pregnancy complications, contraceptives, and menopause. Precision medicine activity in the next 1-2 years is expected to be highest in artificial conception and perinatal testing. This stakeholder discusses challenges in the public and private investment sectors. They are optimistic on new technologies in the fertility / IVF space to improve treatments / outcomes (e.g., AI, ERA) and activity in endometriosis. They are skeptical of the utility / validity of direct-to-consumer modalities and LDTs and are interested to see which companies will make it to the true clinical realm versus stay in the consumer domain. They are excited by activity from Mirvie, Eli Health, Alife, Raydiant Oximetry, NextGen Jane, Qvin, and Gals Bio. They believe investment and prioritization in the future will occur for areas with reimbursement pathways and successful companies will build out the evidence and validation necessary for reimbursement.

‍